News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grant Life Sciences (GLIF.OB) Concludes Licensing Of Point-Of-Care -POC- Diagnostic Platform From AccuDx Corp.


10/19/2005 5:13:00 PM

Grant Life Sciences (OTC Bulletin Board: GLIF) announced today that it has signed a licensing agreement with AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics. Under the agreement, Grant Life Sciences now controls the exclusive rights to AccuDx's rapid tests for HIV-1, HIV-2, and Dengue Fever, as well as AccuDx's proprietary colloidal gold reagent. In addition, Grant Life Sciences has the right to manufacture these products in AccuDx's `maquiladora'-modeled contract manufacturing facility in Tijuana, Mexico. This facility is registered with the FDA and is ISO 9002-certified. Financial terms of the agreement were not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES